Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anthony Elias

Concepts (606)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
104
2024
1862
6.610
 Why?
Antineoplastic Combined Chemotherapy Protocols
91
2024
1355
3.920
 Why?
Sarcoma
32
2022
137
3.460
 Why?
Receptors, Estrogen
22
2021
372
2.500
 Why?
Triple Negative Breast Neoplasms
13
2023
157
2.310
 Why?
Receptor, ErbB-2
21
2024
300
2.150
 Why?
Hematopoietic Stem Cell Transplantation
33
2011
520
1.920
 Why?
Soft Tissue Neoplasms
14
2022
90
1.720
 Why?
Carcinoma, Small Cell
17
2003
158
1.660
 Why?
Carcinoma, Ductal, Breast
7
2018
76
1.580
 Why?
Antineoplastic Agents
31
2023
1879
1.380
 Why?
Neoplasm Recurrence, Local
19
2022
858
1.320
 Why?
Neoadjuvant Therapy
15
2024
304
1.230
 Why?
Receptors, Progesterone
13
2020
319
1.120
 Why?
Biomarkers, Tumor
17
2022
1040
1.100
 Why?
Lung Neoplasms
36
2003
2177
1.070
 Why?
Neoplasm Staging
32
2020
1167
1.070
 Why?
Combined Modality Therapy
50
2021
1121
1.000
 Why?
Mastectomy
9
2018
99
0.990
 Why?
Paclitaxel
13
2024
190
0.940
 Why?
Bone Marrow Transplantation
26
1998
239
0.850
 Why?
Antineoplastic Agents, Alkylating
5
2018
68
0.790
 Why?
Receptors, Androgen
7
2018
131
0.770
 Why?
Female
158
2024
59461
0.770
 Why?
Doxorubicin
20
2020
285
0.740
 Why?
Antibodies, Monoclonal, Humanized
8
2022
663
0.740
 Why?
Humans
210
2024
114616
0.720
 Why?
Antineoplastic Agents, Hormonal
10
2018
138
0.720
 Why?
Bone Neoplasms
6
2022
194
0.720
 Why?
Disease-Free Survival
23
2023
620
0.720
 Why?
Maytansine
3
2021
13
0.700
 Why?
Liposarcoma
4
2023
26
0.690
 Why?
Middle Aged
104
2021
26719
0.690
 Why?
Chemotherapy, Adjuvant
23
2023
332
0.630
 Why?
Dioxoles
2
2015
9
0.600
 Why?
Tetrahydroisoquinolines
2
2015
8
0.600
 Why?
Adult
104
2021
30528
0.580
 Why?
Neoplasm Metastasis
21
2020
522
0.570
 Why?
Ifosfamide
19
1998
32
0.550
 Why?
Androgen Receptor Antagonists
6
2021
30
0.550
 Why?
Phenylthiohydantoin
5
2017
40
0.540
 Why?
Dasatinib
1
2016
46
0.540
 Why?
Neoplasms, Hormone-Dependent
3
2012
38
0.510
 Why?
Aged
59
2023
19061
0.490
 Why?
Cyclophosphamide
29
2020
217
0.490
 Why?
Estrogen Receptor alpha
5
2021
121
0.480
 Why?
Carboplatin
21
2016
135
0.470
 Why?
Treatment Outcome
39
2022
9084
0.470
 Why?
Granulocyte Colony-Stimulating Factor
11
2002
71
0.470
 Why?
Clinical Trials as Topic
19
2018
931
0.460
 Why?
Carcinoma, Non-Small-Cell Lung
16
1997
961
0.450
 Why?
Estrogens
6
2018
312
0.440
 Why?
Drug Administration Schedule
23
2018
718
0.440
 Why?
Neoplasms
19
2009
2097
0.430
 Why?
Dacarbazine
9
2018
99
0.410
 Why?
Trastuzumab
8
2024
89
0.410
 Why?
Tamoxifen
9
2018
191
0.390
 Why?
Pyrimidines
3
2020
376
0.380
 Why?
Survival Rate
18
2021
1644
0.370
 Why?
Survival Analysis
22
2010
1211
0.370
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2013
923
0.370
 Why?
Prognosis
20
2021
3328
0.360
 Why?
Dose-Response Relationship, Drug
17
2017
1842
0.360
 Why?
Neoplasms, Second Primary
3
2022
92
0.360
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2022
49
0.360
 Why?
Drug Resistance, Neoplasm
7
2017
636
0.350
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
7
1999
140
0.350
 Why?
Taxoids
7
2023
93
0.340
 Why?
Breast Neoplasms, Male
3
2018
28
0.340
 Why?
Gene Expression Regulation, Neoplastic
11
2018
1141
0.330
 Why?
Neoplastic Cells, Circulating
2
2020
59
0.310
 Why?
Mesna
12
1998
17
0.300
 Why?
Remission Induction
15
2002
233
0.300
 Why?
Sarcoma, Ewing
3
2022
64
0.300
 Why?
Cisplatin
14
2000
262
0.290
 Why?
Leiomyosarcoma
2
2018
26
0.280
 Why?
Sternum
1
2006
17
0.270
 Why?
Immunohistochemistry
5
2016
1629
0.270
 Why?
Mastectomy, Segmental
2
2009
76
0.260
 Why?
Protein Kinase Inhibitors
4
2019
785
0.250
 Why?
Carcinoma, Ductal
1
2005
11
0.250
 Why?
Ovarian Neoplasms
3
2022
388
0.240
 Why?
Lymph Nodes
1
2007
419
0.240
 Why?
Cell Adhesion Molecules
2
2021
168
0.240
 Why?
Carcinoma
2
2008
198
0.240
 Why?
Risk Reduction Behavior
2
2016
201
0.230
 Why?
Survivors
3
2016
411
0.230
 Why?
Drug Evaluation
19
1998
77
0.230
 Why?
Deoxycytidine
4
2020
138
0.230
 Why?
Weight Loss
4
2016
641
0.230
 Why?
Adjuvants, Immunologic
3
2022
206
0.230
 Why?
Antibodies, Monoclonal
8
2021
1262
0.220
 Why?
Hodgkin Disease
4
2016
120
0.220
 Why?
Ribonuclease III
2
2016
34
0.220
 Why?
Behavior Therapy
2
2016
226
0.220
 Why?
Obesity
4
2018
2507
0.220
 Why?
Thiotepa
13
2002
19
0.220
 Why?
DEAD-box RNA Helicases
2
2016
56
0.220
 Why?
Gene Expression Profiling
6
2017
1518
0.220
 Why?
Alkylating Agents
3
2000
27
0.220
 Why?
Triazoles
2
2022
131
0.220
 Why?
Overweight
3
2016
471
0.210
 Why?
Aged, 80 and over
13
2021
6344
0.210
 Why?
Disease Management
5
2020
560
0.210
 Why?
Referral and Consultation
1
2007
632
0.210
 Why?
Transplantation, Autologous
17
2001
176
0.210
 Why?
Male
61
2022
55549
0.210
 Why?
Salvage Therapy
6
2010
127
0.200
 Why?
Circulating Tumor DNA
1
2022
22
0.200
 Why?
Hydrazines
1
2022
28
0.200
 Why?
Peripheral Blood Stem Cell Transplantation
1
2002
19
0.200
 Why?
Melphalan
9
2002
29
0.200
 Why?
Carcinoma in Situ
2
2012
44
0.200
 Why?
Etoposide
10
2001
148
0.200
 Why?
Tumor Cells, Cultured
9
2020
849
0.190
 Why?
Sarcoma, Synovial
1
2021
11
0.190
 Why?
Hematologic Diseases
6
2008
55
0.190
 Why?
Liposarcoma, Myxoid
1
2021
6
0.190
 Why?
Recombinant Fusion Proteins
1
2024
616
0.190
 Why?
Aromatase Inhibitors
4
2021
49
0.190
 Why?
Endpoint Determination
1
2021
68
0.180
 Why?
Time Factors
12
2020
6112
0.180
 Why?
Hematopoietic Stem Cells
5
1996
343
0.180
 Why?
Sentinel Lymph Node Biopsy
3
2017
99
0.180
 Why?
Leukocytes, Mononuclear
3
2020
493
0.180
 Why?
Cancer Care Facilities
1
2020
29
0.180
 Why?
Indazoles
1
2020
58
0.180
 Why?
Diet
3
2018
1080
0.180
 Why?
Antigens, Neoplasm
4
2021
221
0.180
 Why?
Cell Separation
3
2017
291
0.170
 Why?
Cell Line, Tumor
9
2017
2710
0.170
 Why?
Diphosphonates
1
2020
51
0.170
 Why?
Pyrroles
2
2013
181
0.170
 Why?
Bone Marrow
8
2000
243
0.170
 Why?
Medical Oncology
4
2023
229
0.160
 Why?
Proportional Hazards Models
6
2020
1075
0.160
 Why?
Epithelial-Mesenchymal Transition
1
2020
167
0.160
 Why?
Fluorouracil
7
2013
152
0.160
 Why?
MCF-7 Cells
5
2017
105
0.160
 Why?
Indoles
2
2013
304
0.160
 Why?
Research Design
3
2021
928
0.160
 Why?
Bayes Theorem
4
2024
329
0.160
 Why?
Nitriles
5
2017
149
0.160
 Why?
Benzamides
5
2017
169
0.150
 Why?
Programmed Cell Death 1 Receptor
1
2020
193
0.150
 Why?
Cell Cycle
1
2021
542
0.150
 Why?
Cyclin-Dependent Kinase 4
1
2018
33
0.150
 Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2018
48
0.150
 Why?
Cyclin-Dependent Kinase 6
1
2018
37
0.150
 Why?
Kaplan-Meier Estimate
6
2018
811
0.150
 Why?
Immunotherapy
2
2018
474
0.150
 Why?
Fibromatosis, Aggressive
1
2017
18
0.150
 Why?
Vaccines
1
2022
375
0.140
 Why?
Tetrahydronaphthalenes
1
2017
31
0.140
 Why?
Microbubbles
1
2017
40
0.140
 Why?
Sulfonamides
1
2020
445
0.140
 Why?
Lymph Node Excision
3
2015
139
0.140
 Why?
Valine
1
2017
72
0.140
 Why?
Amyloid Precursor Protein Secretases
1
2017
72
0.140
 Why?
Axilla
3
2017
39
0.140
 Why?
Androgen Antagonists
2
2015
69
0.140
 Why?
Cancer-Associated Fibroblasts
1
2016
10
0.140
 Why?
Infusions, Intravenous
9
2020
371
0.140
 Why?
Gonadal Steroid Hormones
1
2018
124
0.140
 Why?
Neoplasms, Germ Cell and Embryonal
2
1995
62
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
67
0.130
 Why?
Lymphatic Metastasis
3
2017
275
0.130
 Why?
Hematopoietic Cell Growth Factors
2
1995
4
0.130
 Why?
Tumor Suppressor Protein p53
2
2023
445
0.130
 Why?
Ultrasonography, Mammary
1
2016
11
0.130
 Why?
Neoplasm Invasiveness
3
2016
442
0.130
 Why?
Thiazoles
1
2016
110
0.130
 Why?
Antibody Specificity
1
2016
176
0.130
 Why?
Neoplastic Stem Cells
2
2017
329
0.130
 Why?
Maximum Tolerated Dose
1
2016
183
0.130
 Why?
Antibiotics, Antineoplastic
1
2016
109
0.130
 Why?
Disease Progression
7
2018
2380
0.130
 Why?
Mammography
1
2016
105
0.130
 Why?
Quinolines
1
2016
129
0.120
 Why?
Benzimidazoles
1
2016
138
0.120
 Why?
Pyrazoles
1
2018
362
0.120
 Why?
Recurrence
5
2020
935
0.120
 Why?
Exercise
2
2015
1644
0.120
 Why?
Animals
16
2021
31692
0.120
 Why?
Drug Therapy, Combination
4
2014
951
0.120
 Why?
Homeodomain Proteins
2
2018
463
0.120
 Why?
Mice
12
2021
14859
0.120
 Why?
Radiotherapy, Adjuvant
5
2016
182
0.120
 Why?
Administration, Oral
4
2020
728
0.120
 Why?
TOR Serine-Threonine Kinases
1
2017
358
0.120
 Why?
Societies, Medical
1
2018
663
0.120
 Why?
Epigenesis, Genetic
2
2018
520
0.110
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2022
68
0.110
 Why?
Antibodies
1
2016
371
0.110
 Why?
Brain Edema
1
2014
60
0.110
 Why?
Radiotherapy Dosage
3
1999
244
0.110
 Why?
Comorbidity
5
2017
1448
0.110
 Why?
Vascular Neoplasms
1
2013
15
0.110
 Why?
Testicular Neoplasms
1
1995
96
0.110
 Why?
Radiotherapy
3
2015
176
0.110
 Why?
CA-125 Antigen
1
2013
12
0.110
 Why?
Keratins
2
2017
176
0.110
 Why?
Cell Proliferation
6
2017
2186
0.110
 Why?
Cellular Reprogramming
1
2014
84
0.110
 Why?
Bridged-Ring Compounds
3
2020
9
0.110
 Why?
Mercaptoethanol
2
1990
11
0.110
 Why?
Patient Selection
4
2016
641
0.110
 Why?
Apoptosis
6
2023
2362
0.110
 Why?
Retrospective Studies
12
2023
12542
0.110
 Why?
Brain Neoplasms
5
2014
979
0.110
 Why?
Adenocarcinoma
5
2015
795
0.110
 Why?
Chromatin
1
2016
428
0.110
 Why?
Young Adult
9
2021
10455
0.100
 Why?
Bone Marrow Cells
4
2000
267
0.100
 Why?
Gallium Radioisotopes
1
1992
12
0.100
 Why?
Liver Neoplasms
3
2015
506
0.100
 Why?
Carmustine
10
2001
47
0.100
 Why?
Protein-Tyrosine Kinases
2
2022
395
0.100
 Why?
Lymphoma, Non-Hodgkin
3
2001
71
0.100
 Why?
Tumor Microenvironment
3
2021
430
0.100
 Why?
Anthracyclines
3
2023
41
0.100
 Why?
Methotrexate
4
2002
226
0.100
 Why?
Weight Reduction Programs
1
2012
94
0.100
 Why?
Radiosurgery
1
2014
299
0.090
 Why?
Neoplasm, Residual
2
2022
104
0.090
 Why?
Mutation
3
2020
3344
0.090
 Why?
RNA, Catalytic
1
2012
182
0.090
 Why?
Neoplasm Grading
3
2017
242
0.090
 Why?
Aorta
1
2013
386
0.090
 Why?
Neutropenia
5
2013
125
0.090
 Why?
Carcinoma, Lobular
1
2011
44
0.090
 Why?
Multivariate Analysis
4
2013
1430
0.090
 Why?
Adolescent
21
2018
17830
0.090
 Why?
Leukapheresis
4
2001
25
0.090
 Why?
Molecular Targeted Therapy
3
2018
347
0.090
 Why?
Keratin-5
1
2010
46
0.090
 Why?
Angiogenesis Inhibitors
1
2012
214
0.090
 Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
100
0.090
 Why?
Peptide Mapping
1
2010
60
0.090
 Why?
Databases, Protein
1
2010
59
0.080
 Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2010
134
0.080
 Why?
Urinary Tract
1
1990
36
0.080
 Why?
Postmenopause
2
2017
303
0.080
 Why?
United States
9
2023
12176
0.080
 Why?
CD146 Antigen
2
2021
35
0.080
 Why?
Benzenesulfonates
1
2009
20
0.080
 Why?
BRCA2 Protein
1
2009
41
0.080
 Why?
Health Facilities
1
2009
72
0.080
 Why?
Observer Variation
1
2010
295
0.080
 Why?
Pregnancy Complications, Neoplastic
1
2009
50
0.080
 Why?
Thrombophilia
1
2009
67
0.080
 Why?
Patient Care
1
2009
101
0.080
 Why?
Follow-Up Studies
4
2021
4411
0.080
 Why?
Biopsy
2
2018
1036
0.080
 Why?
Randomized Controlled Trials as Topic
6
2000
1214
0.080
 Why?
Xenograft Model Antitumor Assays
3
2017
698
0.080
 Why?
Mice, Nude
3
2017
630
0.080
 Why?
Fatigue
3
2018
294
0.070
 Why?
Perimenopause
1
2008
61
0.070
 Why?
In Situ Hybridization
2
2010
292
0.070
 Why?
Bone Marrow Diseases
4
2000
18
0.070
 Why?
Quality of Life
2
2015
2353
0.070
 Why?
In Situ Hybridization, Fluorescence
1
2008
309
0.070
 Why?
Risk Assessment
2
2020
2967
0.070
 Why?
Reproducibility of Results
2
2016
2762
0.070
 Why?
Blotting, Western
1
2010
1147
0.070
 Why?
Pneumonectomy
3
1997
125
0.070
 Why?
Sputum
1
1988
285
0.070
 Why?
Clinical Decision-Making
2
2020
268
0.070
 Why?
Pyridines
1
2009
425
0.060
 Why?
Neoplasm Proteins
2
2007
384
0.060
 Why?
Hepatic Veno-Occlusive Disease
2
1998
11
0.060
 Why?
Risk Factors
6
2020
8628
0.060
 Why?
Predictive Value of Tests
2
2016
1796
0.060
 Why?
Magnetic Resonance Imaging
1
2016
3039
0.060
 Why?
Positron-Emission Tomography
1
2006
259
0.060
 Why?
Life Tables
2
2002
17
0.060
 Why?
Anilides
2
2016
67
0.060
 Why?
Enzyme Inhibitors
1
2008
750
0.060
 Why?
MicroRNAs
1
2010
600
0.060
 Why?
Signal Transduction
5
2018
4509
0.060
 Why?
Mammaplasty
2
2016
68
0.060
 Why?
Receptor, TIE-2
1
2024
12
0.060
 Why?
Genes, Neoplasm
1
2004
20
0.060
 Why?
Forecasting
3
2000
330
0.060
 Why?
Ricin
2
1997
8
0.060
 Why?
Patient Care Planning
1
2005
139
0.060
 Why?
Proteomics
1
2010
835
0.060
 Why?
Oligonucleotide Array Sequence Analysis
3
2012
740
0.060
 Why?
Thrombocytopenia
3
2013
177
0.060
 Why?
Transcriptome
2
2023
724
0.060
 Why?
Up-Regulation
2
2017
807
0.060
 Why?
Activating Transcription Factor 4
1
2023
18
0.060
 Why?
Proteasome Inhibitors
1
2023
40
0.050
 Why?
Proto-Oncogene Proteins c-mdm2
1
2023
56
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2000
82
0.050
 Why?
Cyclin E
1
2022
21
0.050
 Why?
G(M2) Ganglioside
1
2022
1
0.050
 Why?
Injection Site Reaction
1
2022
3
0.050
 Why?
Proteasome Endopeptidase Complex
1
2023
133
0.050
 Why?
Tomography, X-Ray Computed
2
2015
2279
0.050
 Why?
Oncogene Proteins
1
2022
53
0.050
 Why?
Clinical Trials, Phase I as Topic
2
2020
45
0.050
 Why?
Ribose
1
2022
18
0.050
 Why?
Luminescent Measurements
1
2003
74
0.050
 Why?
Carbolines
1
2022
27
0.050
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2022
16
0.050
 Why?
Blood Transfusion, Autologous
2
1993
19
0.050
 Why?
Adenosine Diphosphate
1
2022
81
0.050
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2022
76
0.050
 Why?
Oncogenes
1
2022
103
0.050
 Why?
Actuarial Analysis
2
1993
21
0.050
 Why?
Gene Expression
2
2020
1421
0.050
 Why?
Longitudinal Studies
2
2012
2387
0.050
 Why?
Colony-Forming Units Assay
4
1996
88
0.050
 Why?
Cell Division
2
2001
758
0.050
 Why?
Age Factors
3
2018
2894
0.050
 Why?
Phthalazines
1
2021
38
0.050
 Why?
Clodronic Acid
1
2020
8
0.040
 Why?
Estradiol
2
2016
455
0.040
 Why?
Transplantation Immunology
1
2000
30
0.040
 Why?
Progesterone
1
2002
232
0.040
 Why?
Ligands
1
2022
561
0.040
 Why?
Phosphatidylinositol 3-Kinases
1
2022
329
0.040
 Why?
Topoisomerase I Inhibitors
1
1999
15
0.040
 Why?
Polymerase Chain Reaction
1
2003
993
0.040
 Why?
Leucovorin
2
1997
43
0.040
 Why?
Prospective Studies
4
2022
6214
0.040
 Why?
Thoracotomy
2
1997
75
0.040
 Why?
Bone Density Conservation Agents
1
2020
62
0.040
 Why?
Dendritic Cells
2
2000
435
0.040
 Why?
Hematopoietic Stem Cell Mobilization
1
1999
20
0.040
 Why?
Mechlorethamine
1
2000
63
0.040
 Why?
Myelodysplastic Syndromes
1
2001
119
0.040
 Why?
Drug Resistance
1
1999
158
0.040
 Why?
Cross-Over Studies
1
2020
440
0.040
 Why?
Neoplasms, Experimental
1
2000
151
0.040
 Why?
Piperazines
1
2021
309
0.040
 Why?
Heterocyclic Compounds, 3-Ring
1
2019
28
0.040
 Why?
Cell Cycle Proteins
1
2022
551
0.040
 Why?
Cluster Analysis
2
2012
455
0.040
 Why?
Receptors, Steroid
1
2019
47
0.040
 Why?
Polydeoxyribonucleotides
1
1998
12
0.040
 Why?
Colony-Stimulating Factors
2
1988
32
0.040
 Why?
Child
7
2022
18402
0.040
 Why?
Leukemia
1
2001
209
0.040
 Why?
Etanidazole
1
1998
1
0.040
 Why?
Loss of Function Mutation
1
2018
36
0.040
 Why?
Enterocolitis, Pseudomembranous
1
1998
25
0.040
 Why?
Nervous System
2
1997
63
0.040
 Why?
Granulocytes
3
1995
77
0.040
 Why?
Aurora Kinase A
1
2018
51
0.040
 Why?
Expectorants
1
1998
24
0.040
 Why?
Growth Substances
2
1988
138
0.040
 Why?
Disease Susceptibility
1
2020
316
0.040
 Why?
Statistics, Nonparametric
1
1999
385
0.040
 Why?
Nausea
1
2018
101
0.040
 Why?
Retreatment
1
2018
67
0.040
 Why?
Mediastinum
1
1998
22
0.040
 Why?
Administration, Intravenous
1
2018
124
0.040
 Why?
Epithelial Cell Adhesion Molecule
1
2017
10
0.040
 Why?
Medicare
1
2023
665
0.040
 Why?
Double-Blind Method
1
2022
1660
0.040
 Why?
Extremities
2
1989
113
0.040
 Why?
Breast
1
2018
139
0.040
 Why?
Watchful Waiting
1
2018
55
0.040
 Why?
SEER Program
1
2018
196
0.040
 Why?
Cohort Studies
4
2001
4894
0.040
 Why?
Diarrhea
1
2018
171
0.040
 Why?
Cell Hypoxia
1
1998
220
0.040
 Why?
Thorax
1
1997
40
0.040
 Why?
Everolimus
1
2017
61
0.040
 Why?
Random Allocation
2
1988
335
0.030
 Why?
Immunotoxins
1
1997
33
0.030
 Why?
Phosphoramide Mustards
1
2016
1
0.030
 Why?
Heterografts
1
2017
117
0.030
 Why?
Proto-Oncogene Proteins c-akt
1
2019
398
0.030
 Why?
Cyclohexanes
1
2016
22
0.030
 Why?
Cytochrome P-450 CYP3A
1
2017
61
0.030
 Why?
Cell Survival
1
2000
1020
0.030
 Why?
Lymphoma, Large B-Cell, Diffuse
1
1998
98
0.030
 Why?
Carcinogenesis
1
2018
177
0.030
 Why?
Placebos
1
2016
197
0.030
 Why?
Gene Knockdown Techniques
1
2017
299
0.030
 Why?
Antineoplastic Agents, Immunological
1
2018
152
0.030
 Why?
Fibrinolytic Agents
1
1998
234
0.030
 Why?
Injections, Intravenous
2
1993
198
0.030
 Why?
Kidney
2
1995
1187
0.030
 Why?
Blood Specimen Collection
1
1995
31
0.030
 Why?
Fertility Preservation
1
2016
46
0.030
 Why?
Mortality
1
1997
287
0.030
 Why?
Genetic Therapy
1
1997
257
0.030
 Why?
Organoplatinum Compounds
3
1990
37
0.030
 Why?
Antidotes
1
1997
135
0.030
 Why?
Transcriptional Activation
1
2017
337
0.030
 Why?
Pulmonary Fibrosis
3
1993
323
0.030
 Why?
Vincristine
1
1995
98
0.030
 Why?
Blood Component Transfusion
2
1994
78
0.030
 Why?
Digestive System
1
1995
27
0.030
 Why?
Weight Gain
1
2018
453
0.030
 Why?
Fertility
1
2016
130
0.030
 Why?
Adipose Tissue
1
2018
539
0.030
 Why?
Interleukin-3
1
1994
23
0.030
 Why?
Hormones
1
2015
132
0.030
 Why?
Bacterial Infections
1
1996
218
0.030
 Why?
Odds Ratio
1
2017
953
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2017
238
0.030
 Why?
Tosyl Compounds
1
2014
14
0.030
 Why?
Drug Discovery
1
2015
123
0.030
 Why?
HEK293 Cells
1
2016
590
0.030
 Why?
Protein Transport
1
2015
395
0.030
 Why?
Alternative Splicing
1
2015
187
0.030
 Why?
Hand-Foot Syndrome
1
2013
2
0.030
 Why?
Erythropoietin
1
1994
72
0.030
 Why?
Capecitabine
1
2013
45
0.030
 Why?
Cell Nucleus
1
2016
554
0.030
 Why?
Necrosis
1
2014
211
0.030
 Why?
Transplantation, Heterologous
1
2014
181
0.030
 Why?
Neoplasm Transplantation
1
2014
228
0.030
 Why?
Camptothecin
1
1994
96
0.030
 Why?
Gene Silencing
1
2014
171
0.030
 Why?
Binding Sites
1
2016
1168
0.030
 Why?
Child, Preschool
5
2013
9106
0.030
 Why?
Nutritional Status
1
2015
287
0.030
 Why?
Sensitivity and Specificity
2
2000
1691
0.030
 Why?
Blood Cells
1
1993
38
0.030
 Why?
Anemia
1
1994
143
0.030
 Why?
Recombinant Proteins
5
1997
1230
0.030
 Why?
Feasibility Studies
4
1998
739
0.030
 Why?
Energy Intake
1
2015
427
0.030
 Why?
CD24 Antigen
1
2012
20
0.030
 Why?
Counseling
1
2015
342
0.030
 Why?
Radionuclide Imaging
1
1992
115
0.030
 Why?
Models, Biological
1
1999
1620
0.030
 Why?
Diet, Reducing
1
2012
76
0.030
 Why?
Psychotherapy, Group
1
2012
61
0.030
 Why?
Hyaluronan Receptors
1
2012
90
0.030
 Why?
Antigens, CD34
3
1996
89
0.020
 Why?
Leukocyte Count
4
1996
293
0.020
 Why?
Vascular Endothelial Growth Factor Receptor-1
1
2012
66
0.020
 Why?
Disease Models, Animal
1
2021
3531
0.020
 Why?
Mice, SCID
1
2012
314
0.020
 Why?
Tumor Burden
1
2012
259
0.020
 Why?
Logistic Models
1
2016
1840
0.020
 Why?
Colorado
1
2020
4099
0.020
 Why?
Internship and Residency
1
1980
926
0.020
 Why?
Fluorescent Antibody Technique
2
1990
397
0.020
 Why?
Gene Regulatory Networks
1
2012
228
0.020
 Why?
Biopsy, Needle
1
2011
182
0.020
 Why?
Mice, Inbred NOD
1
2012
555
0.020
 Why?
Graft Survival
1
1993
446
0.020
 Why?
Blast Crisis
1
1990
20
0.020
 Why?
Health Status
1
2015
722
0.020
 Why?
Cytokines
1
1998
1840
0.020
 Why?
Chromosomes, Human, Pair 9
1
1990
43
0.020
 Why?
Hypertension
1
2018
1056
0.020
 Why?
Kidney Diseases
2
1991
350
0.020
 Why?
Pemetrexed
1
2010
27
0.020
 Why?
Chromosomes, Human, Pair 22
1
1990
38
0.020
 Why?
Immunoblotting
1
2010
283
0.020
 Why?
Glutamates
1
2010
57
0.020
 Why?
Magnetics
1
1990
39
0.020
 Why?
Antibodies, Anti-Idiotypic
1
1990
53
0.020
 Why?
Urologic Diseases
1
1990
35
0.020
 Why?
DNA Methylation
1
2014
495
0.020
 Why?
Guanine
1
2010
76
0.020
 Why?
Cell Movement
1
2014
868
0.020
 Why?
Health Behavior
1
2015
704
0.020
 Why?
Chromosome Aberrations
1
1990
135
0.020
 Why?
Real-Time Polymerase Chain Reaction
1
2010
313
0.020
 Why?
Promoter Regions, Genetic
1
2014
1131
0.020
 Why?
Microspheres
1
1990
123
0.020
 Why?
Spinal Cord Neoplasms
1
1989
37
0.020
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
1990
95
0.020
 Why?
Lymphoma
1
1990
177
0.020
 Why?
Blood
1
1990
96
0.020
 Why?
Clone Cells
1
1990
247
0.020
 Why?
Pregnancy Trimester, Second
1
2009
66
0.020
 Why?
Macrophages
2
1995
1261
0.020
 Why?
Central Nervous System Diseases
1
1990
61
0.020
 Why?
Creatinine
1
1991
425
0.020
 Why?
Histones
1
2014
534
0.020
 Why?
Hematuria
1
1989
7
0.020
 Why?
Vinblastine
2
2001
63
0.020
 Why?
Exercise Therapy
1
2012
350
0.020
 Why?
Immunophenotyping
2
2000
274
0.020
 Why?
Niacinamide
1
2009
63
0.020
 Why?
Pregnancy Trimester, First
1
2009
125
0.020
 Why?
False Negative Reactions
1
1988
48
0.020
 Why?
Leukopenia
1
1988
27
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
171
0.020
 Why?
Phenylurea Compounds
1
2009
82
0.020
 Why?
False Positive Reactions
1
1988
109
0.020
 Why?
Transfection
1
2010
866
0.020
 Why?
Drug Interactions
1
1990
338
0.020
 Why?
Hospitals, Veterans
1
2009
244
0.020
 Why?
Electrophoresis
1
1988
26
0.020
 Why?
Perilipin-1
1
2008
16
0.020
 Why?
Estrogen Receptor Modulators
1
2008
17
0.020
 Why?
Staining and Labeling
1
1988
134
0.020
 Why?
Vimentin
1
1988
58
0.020
 Why?
Biomarkers
1
2018
3405
0.020
 Why?
S100 Proteins
1
2008
38
0.020
 Why?
Nervous System Diseases
1
1991
253
0.020
 Why?
Central Nervous System
1
1990
235
0.020
 Why?
Community Health Services
1
2009
212
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2084
0.020
 Why?
Androstadienes
1
2008
97
0.020
 Why?
Sarcoma, Kaposi
1
1988
68
0.020
 Why?
Health Knowledge, Attitudes, Practice
1
2015
1183
0.020
 Why?
Lung Diseases
2
1992
701
0.020
 Why?
Academic Medical Centers
1
2009
410
0.020
 Why?
Bone Marrow Purging
2
1996
3
0.020
 Why?
Clinical Trials, Phase II as Topic
2
2000
59
0.020
 Why?
Heart Diseases
1
1990
330
0.020
 Why?
Risk
2
2000
812
0.020
 Why?
Gastrointestinal Diseases
1
2008
182
0.020
 Why?
Stem Cell Transplantation
1
2007
149
0.020
 Why?
Phosphoproteins
1
2008
298
0.020
 Why?
Immunoglobulin G
1
1990
770
0.020
 Why?
Bevacizumab
1
2006
115
0.020
 Why?
Body Mass Index
1
2012
1956
0.020
 Why?
Quality of Health Care
1
2009
573
0.020
 Why?
Melanoma
2
1988
619
0.020
 Why?
Carrier Proteins
1
2008
695
0.010
 Why?
Brain
1
2014
2371
0.010
 Why?
Phenotype
1
2010
2796
0.010
 Why?
Cells, Cultured
1
1990
3881
0.010
 Why?
Carcinoma, Lewis Lung
1
2001
13
0.010
 Why?
Hemorrhage
2
1998
620
0.010
 Why?
Drug Synergism
1
2001
316
0.010
 Why?
Phytohemagglutinins
1
2000
27
0.010
 Why?
CD4-CD8 Ratio
1
2000
19
0.010
 Why?
Hypersensitivity, Delayed
1
2000
27
0.010
 Why?
Lymphocyte Culture Test, Mixed
1
2000
41
0.010
 Why?
Microcomputers
1
2000
14
0.010
 Why?
Louisiana
1
2000
23
0.010
 Why?
France
1
2000
34
0.010
 Why?
Skin Tests
1
2000
116
0.010
 Why?
Philadelphia
1
2000
46
0.010
 Why?
Immunoglobulins
1
2000
142
0.010
 Why?
Lung
1
1992
3557
0.010
 Why?
Automation
1
2000
73
0.010
 Why?
Immunity
1
2000
121
0.010
 Why?
Heart Failure
1
1992
1945
0.010
 Why?
Personnel Selection
1
1980
62
0.010
 Why?
Marriage
1
1980
106
0.010
 Why?
Lipopolysaccharide Receptors
1
1999
81
0.010
 Why?
Multicenter Studies as Topic
1
2000
248
0.010
 Why?
Pilot Projects
2
1994
1372
0.010
 Why?
Infant, Newborn
1
2009
5040
0.010
 Why?
Interleukin-4
1
1999
206
0.010
 Why?
Thalassemia
1
1998
7
0.010
 Why?
Receptors, Purinergic P1
1
1998
24
0.010
 Why?
Reference Values
1
2000
742
0.010
 Why?
Bilirubin
1
1998
88
0.010
 Why?
Microscopy, Fluorescence
1
2000
396
0.010
 Why?
Acute Disease
1
2001
910
0.010
 Why?
Pregnancy
1
2009
5517
0.010
 Why?
Multiple Organ Failure
1
1998
146
0.010
 Why?
Killer Cells, Natural
1
2000
380
0.010
 Why?
Filgrastim
1
1997
10
0.010
 Why?
Heparin
1
1998
224
0.010
 Why?
Adenoviruses, Human
1
1996
24
0.010
 Why?
Lymphoma, B-Cell
1
1998
86
0.010
 Why?
Lymphocyte Activation
1
2000
1037
0.010
 Why?
Freezing
1
1996
84
0.010
 Why?
Tissue Plasminogen Activator
1
1998
225
0.010
 Why?
Lymphocyte Depletion
1
1996
116
0.010
 Why?
Genes, Reporter
1
1996
257
0.010
 Why?
Immunoconjugates
1
1997
87
0.010
 Why?
Drug Tolerance
1
1995
79
0.010
 Why?
Treatment Failure
1
1996
331
0.010
 Why?
Incidence
1
2001
2311
0.010
 Why?
Reticulocyte Count
1
1994
5
0.010
 Why?
Kidney Function Tests
1
1995
140
0.010
 Why?
Antigens, CD
1
1996
442
0.010
 Why?
Topotecan
1
1994
10
0.010
 Why?
Glioblastoma
1
1996
253
0.010
 Why?
Urinary Bladder Diseases
1
1993
18
0.010
 Why?
Chromatography, High Pressure Liquid
1
1995
470
0.010
 Why?
Flow Cytometry
1
1996
1083
0.010
 Why?
Heart
1
1997
612
0.010
 Why?
Boston
1
1993
75
0.010
 Why?
Iron
1
1994
233
0.010
 Why?
Palliative Care
1
1998
641
0.010
 Why?
Cell Line
1
1996
2635
0.010
 Why?
Immunologic Factors
1
1993
220
0.010
 Why?
Cystitis
1
1990
20
0.010
 Why?
Prostatic Neoplasms
1
1996
921
0.010
 Why?
Introns
1
1990
227
0.010
 Why?
Metabolic Clearance Rate
1
1989
102
0.010
 Why?
Platinum
1
1989
38
0.010
 Why?
Drug Combinations
1
1990
287
0.010
 Why?
Brain Diseases
1
1990
124
0.000
 Why?
Bone Marrow Examination
1
1988
6
0.000
 Why?
Platelet Count
1
1988
81
0.000
 Why?
Erythrocyte Count
1
1988
19
0.000
 Why?
Methods
1
1988
58
0.000
 Why?
Pelvic Neoplasms
1
1988
18
0.000
 Why?
Erythroblasts
1
1988
12
0.000
 Why?
Acute Kidney Injury
1
1995
637
0.000
 Why?
DNA Damage
1
1990
351
0.000
 Why?
Pneumonia
1
1992
567
0.000
 Why?
Fever
1
1988
280
0.000
 Why?
Statistics as Topic
1
1987
292
0.000
 Why?
Elias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (606) concept(s)
_
Co-Authors Expand Description
See all (51) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)